Literature DB >> 2104571

Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and long-term effects.

S M Pierce1, P D Barnes, J S Loeffler, C McGinn, N J Tarbell.   

Abstract

We reviewed 24 children who had symptomatic gliomas that involved the optic chiasm and were treated with definitive radiation therapy from 1971 to 1986. In eight patients (33%), histologic confirmation of low-grade astrocytoma was obtained. Patients had radiation therapy only if there was evidence of visual deterioration or other clinical or radiographic evidence of disease progression. Radiation doses ranged from 4500 to 5660 cGy (median, 5400 cGy) with up to a 17-year follow-up period (median, 6 years). The 6-year actuarial freedom from disease progression and overall 6-year survival are 88% and 100%, respectively. Visual improvement or stabilization was seen in 21 (91%) patients after radiation. A high incidence of endocrine abnormalities is reported, with 15 of the 18 patients evaluated after treatment showing growth hormone deficiency. We conclude that definitive radiation therapy is associated with tumor control in most of the patients with progressive optic chiasm gliomas. However, neuropsychiatric and endocrine abnormalities are significant problems that need additional evaluation in these children.

Entities:  

Mesh:

Year:  1990        PMID: 2104571     DOI: 10.1002/1097-0142(19900101)65:1<45::aid-cncr2820650111>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

Review 1.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

2.  fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies.

Authors:  P de Blank; K Cole; L Kersun; A Green; J J Wilkes; J Belasco; R Bagatell; L C Bailey; M J Fisher
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

3.  A clinical study of type 1 neurofibromatosis in north west England.

Authors:  J M McGaughran; D I Harris; D Donnai; D Teare; R MacLeod; R Westerbeek; H Kingston; M Super; R Harris; D G Evans
Journal:  J Med Genet       Date:  1999-03       Impact factor: 6.318

4.  Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy.

Authors:  Richard M Awdeh; Erin N Kiehna; Richard D Drewry; Natalie C Kerr; Barrett G Haik; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-18       Impact factor: 7.038

5.  Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study.

Authors:  V M Aquino; D W Fort; B A Kamen
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

Review 6.  Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications.

Authors:  Klaus-Martin Kreusel
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

7.  Halo ring supporting the Brown-Roberts-Wells stereotactic frame for fractionated radiotherapy.

Authors:  S Carini; G Scielzo; F Grillo Ruggieri; F Bistolfi; M Ravegnani; L Andreussi
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 8.  Special issues in the management of gliomas in children with neurofibromatosis 1.

Authors:  I F Pollack; J J Mulvihill
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

9.  Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era.

Authors:  C Cappelli; J Grill; M Raquin; A Pierre-Kahn; A Lellouch-Tubiana; M J Terrier-Lacombe; J L Habrand; D Couanet; R Brauner; D Rodriguez; O Hartmann; C Kalifa
Journal:  Arch Dis Child       Date:  1998-10       Impact factor: 3.791

10.  Analysis of 20 primarily surgically treated chiasmatic/hypothalamic pilocytic astrocytomas.

Authors:  J M Valdueza; F Lohmann; O Dammann; C Hagel; B Eckert; N Freckmann
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.